Neurogastrx Secures $60 Million In Series B Financing And Expands Management Team To Advance Its Pipeline Of Transformative Investigational Therapies For Gastrointestinal Disorders
Amount Raised
$60 Million
Round Type
Series B
WoburnBiotechnologyHealth CareScience And EngineeringInternet ServicesDescription
Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today the successful completion of a $60 million Series B crossover round led by Vivo Capital. Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors who also participated in the Series A financing.
Quick answer
Neurogastrx raised $60 Million in a Series B round, dated August 26, 2021. Neurogastrx is based in Woburn, Massachusetts, United States.
- How much did Neurogastrx raise?
- Neurogastrx raised $60 Million in a Series B round on August 26, 2021.
- What does Neurogastrx do?
- Neurogastrx, Inc. is a privately held specialty pharmaceutical company developing transformative therapies to advance the treatment of GI disorders for which meaningful therapeutic innovation is required to satisfy..
- Where is Neurogastrx based and how big is it?
- Neurogastrx is based in Woburn, Massachusetts, United States.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Internet Services around the same time
Companies in the same sectors as Neurogastrx that raised within 45 days of this round, from Fundz verified event records.
- Exscientia raised $510M (Post-IPO Equity) on October 5, 2021.
- Envisagenics raised an undisclosed amount (Series A) on September 29, 2021.
- Athos Therapeutics, Inc. raised $13M on September 28, 2021.
- Delix Therapeutics raised $70M (Series A) on September 27, 2021.
- Garuda Therapeutics raised $48M on September 24, 2021.
- Garuda Therapeutics raised $72M (Series A) on September 23, 2021.
Who to call at Neurogastrx, and when
A new round usually means Neurogastrx is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Neurogastrx raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Neurogastrx, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Neurogastrx. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Neurogastrx raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansNeurogastrx raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.